PTC Therapeutics, Inc. (PTCT) stock

PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3031% above fair value

$63.49+0.13 (+0.21%)

Close on Nov 13, 2026Market cap $5.30BP/E –Yield –

PTC Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

PTC Therapeutics's EV/EBITDA was 20.8× on Nov 11, 2026, against 2.9× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	20.8×	+15.1
2025	Dec 31, 2025	5.8×	−173.4
2024	Dec 31, 2024	179.2×	–

Parsed from the XBRL in PTC Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PTCT.

Revenue growth-35.1% · median 14.8%

Operating margin12.8% · median -37.1%

Net margin-9.2% · median -39.9%

Advertisement
300 × 250

See a number that looks wrong?